Company News

October 3, 2024

Shape Therapeutics Unveils Major Advances in AI-Powered Platform for Precision RNA Editing

June 25, 2024

Shape Therapeutics Appoints Healthcare Industry Leaders David Epstein and Todd Simpson to its Board of Directors

May 9, 2024

Shape Therapeutics RNAfix® Editing Platform Achieves >90% Editing in Mouse and Non-Human Primate Brain

May 2, 2024

Shape Therapeutics Announces Appointment of Matt Valentino as Chief People Officer

April 30, 2024

Shape Therapeutics to Showcase RNA Editing in the Brain and Validation of their Stable AAV Producer Cell Line at ASGCT 2024

November 30, 2023

ShapeTX Expands Strategic Collaboration with Roche with Addition of a New Target

September 7, 2023

Otsuka collaborates with ShapeTX to develop novel AAV gene therapies for ocular diseases

June 20, 2023

ShapeTX Announces the Appointment of Adrian W. Briggs, Ph.D. As Chief Technology Officer

May 4, 2023

ShapeTX Announces Seven Presentations at ASGCT 2023 Showcasing the Potential of Generative AI and RNA in CNS Disorders and Beyond

January 5, 2023

ShapeTX to Showcase Groundbreaking Advances in CNS in vivo RNA Editing, CNS-Targeting AAVs, and TruStable™ AAV Manufacturing at the J.P. Morgan 41st Annual Healthcare Conference

September 12, 2022

Shape Therapeutics named one of Fierce Biotech’s “Fierce 15” Companies of 2022

May 12, 2022

Shape Therapeutics to Present Data Highlighting Advances in Its AI-Driven RNA Technology Platforms at the 2022 ASGCT Annual Meeting

April 26, 2022

Shape Therapeutics Welcomes Google and Stripe Veterans Gayathri Rajan, Kelly Sims to its Board of Directors

January 6, 2022

Shape Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

November 9, 2021

Shape Therapeutics Appoints David J. Huss, Ph. D., as Chief Scientific Officer and Lisa Taylor Ash, J. D., as General Counsel

August 24, 2021

Shape Therapeutics enters into a strategic research collaboration with Roche to advance breakthrough AAV-based RNA editing technology for neuroscience and rare disease indications

July 15, 2021

Shape Therapeutics Secures $112 Million in Series B Financing to Advance Breakthrough RNA Technology Platforms to Democratize Gene Therapy

May 28, 2021